tbuckley/cabot-search huggingface dataset:
Abdominal Surgery
Authors: Arthur W. Allen
Journal: New England Journal of Medicine (1948)

The DuodenumShapiro and Robillard61 discuss anomalies of the blood supply of the duodenum. There are many variations in the vascular arrangement in this region, and unless these are recognized, avascularization of the duodenal stump following gastrectomy may result in necrosis and leakage. Avoidance of this complication is simple if the surgeon frees the duodenum from the pancreas only enough to allow an adequate turn-in of the duodenal stump. This is best accomplished if the adherent and inflammatory area about the ulcer site is approached after the stomach has been transected. Freeing the duodenum distal to the ulcer as a . . .
Prophylaxis of malaria
Authors: C. J. Brown
Journal: JAMA (1979)

<h3>To the Editor.—</h3> I want to add my support to the observation by B. H. Kean, MD (241:395, 1979) of a case of chloroquin-resistant falciparum malaria. From September 1977 through May 1978,I worked at the Baptist Medical Center in Nalerigu, Ghana, West Africa. Nalerigu is situated in the savannah lands of the Northern Region. Malaria is a year-round problem there, becoming epidemic during rainy seasons. The hospital has been serving that region for almost 20 years, treating 300 to 500 patients daily. At least one third of those require treatment for malaria, the standard adult therapy being chloroquin phosphate, 4 g administered during a three-day period, frequently with the addition of sulfadiazine. Despite this regimen, many patients are hospitalized with chronic malaria, which is confirmed by daily peripheral blood smears. Hospitalization is necessary to rule out failure to take medications properly. I had one case that proved resistant to a
ESGE Newsletter
Journal: Endoscopy (2008)

Starting October 18 the stage in Vienna will be set for what is the highlight of the year – from a European gastroenterologist's point of view: the 16th UEGW 2008. As in previous years ESGE will be responsible for the endoscopic content of the Postgraduate Teaching Programme and will be offering several activities in the ESGE Learning Area throughout the week. A brochure outlining the complete scope of events hosted by ESGE is included as a supplement in this issue of Endoscopy.
<i>CUL4A and ERCC1</i> genesas predictive factors for trabectedin efficacy in advanced soft tissue sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) study.
Authors: Javier Martin Broto, Antonio Fernandez-Serra, Antonio Lopez-Pousa, Antonio Gutierrez, Ramon De Las Penas, Javier Martinez-Trufero, Josefina Cruz, Rosa Maria Alvarez, Ricardo Cubedo, Andres Redondo, Juan Antonio Carrasco, Jose A. Lopez-Martin, María Ángeles Sala, Isabel Sevilla, Carmen Balana, María Ángeles Vaz Salgado, Ana De Juan, Andres Poveda, Nadia Hindi, Jose Antonio Lopez-Guerrero
Journal: Journal of Clinical Oncology (2016)

11048 Background: The most studied predictive factors for trabectedin (T) efficacy in STS are related to the nucleotide excision repair (NER) and homologous recombination (HHR) genes. Thus, T is more active in the context of high expression levels of NER genes (ERCC1 and ERCC5) and low expression level of HHR genes (BRCA1). A link between NER and the ubiquitin-proteasome system was emerged from the findings that DDB1-DDB2 is part of a CUL4A ubiquitin ligase. The aim was to analyze NER, CUL4A and HHR gene expressions as potential predictive factors for trabectedin efficacy in STS. Methods: This is a translational part of a randomized phase II trial comparing T+Doxorubicin (D) with D alone in advanced STS patients. The trial was stopped for futility after an accrual of 115 patients. The expression level of the genes studied (ERCC1, ERCC5, CUL4A y BRACA1) was evaluated by Real Time PCR using the TaqMan assays. Cut-off used to define high or low expression was the median value for each gene. Progression free survival (PFS) and Overall survival (OS) were the clinical outcomes Results: At the interim analysis time, there were 70 progression events out of 113 evaluable patients and the median of follow up was 13 months. There were 65 cases with paraffin embedded blocks available for mRNA expression. In the global series, no significant differences, in terms of PFS or OS, were seen among the analyzed genes. Only high CUL4A expression showed a trend towards a better PFS (8.1 vs 4.6 months, p = 0.13). Similarly, in the D arm, no differences were seen in PFS or OS for any analyzed gene. However, in the TD arm high expression of CUL4A was significantly associated with a better PFS (8.1 vs 1.7 months, p = 0.015) and OS (21.8 vs 9.4 months, p = 0.041). Additionally, high expression of ERCC1 was related with a significantly better PFS (8.2 vs 2.9 months, p = 0.031). Curiously, high expression of CUL4A and ERCC1 were significantly associated with longer disease interval Conclusions: CUL4A and ERCC1 showed to be the most relevant predictive factors for T in advanced STS and were significantly related with a longer interval of recurrence. A validation series of 300 patients is currently being evaluated
INTERMEDIARY METABOLISM OF FAT
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Imaging
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Radium-223 re-treatment in an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases: 2-year follow-up.
Authors: A. Oliver Sartor, Daniel Heinrich, Neil Mariados, María José Méndez-Vidal, Daniel Keizman, Camilla Thellenberg Karlsson, Avivit Pe'er, Giuseppe Procopio, Stephen Jay Frank, Kalevi Pulkkanen, Eli Rosenbaum, Stefano Severi, Jose Manuel Trigo Perez, Lucia Trandafir, Volker Jean Wagner, Rui Li, Luke T. Nordquist
Journal: Journal of Clinical Oncology (2018)

5022 Background: Radium-223 (Ra-223) treatment (tx) is indicated for patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) (6 × 55 kBq/kg IV injections [inj]; 1 inj q4wk). Early results of an international, open-label, phase 1/2 study (NCT01934790) showed that re-treating pts with Ra-223 was well tolerated with favorable effects on disease progression. Here we report safety and efficacy findings from a 2-year follow-up. Methods: Pts with CRPC and bone mets who completed 6 initial Ra-223 inj with no disease progression in bone and later progressed were eligible for Ra-223 re-tx (6 additional Ra-223 inj), provided that hematologic parameters were adequate. No concomitant cytotoxic chemotherapy was allowed; other concomitant agents for prostate cancer (including abiraterone and enzalutamide) were allowed at investigator discretion. The primary objective was safety. Exploratory objectives were time to radiographic bone progression, radiographic progression-free survival (rPFS), overall survival (OS), time to first symptomatic skeletal event (SSE), and SSE-free survival, all calculated from re-tx start. Pts will be followed for safety up to 7 years after last Ra-223 dose; an active 2-year follow-up evaluated exploratory objectives. Safety results from the active follow-up period and updated efficacy are reported. Results: 44 pts were re-treated with Ra-223; 29 (66%) completed all 6 inj (median number inj = 6). 34 (77%) of 44 pts entered active follow-up, during which no new safety concerns were noted. There were no serious drug-related adverse events. 26 (59%) of 44 pts had an rPFS event (radiographic progression or death); median rPFS was 12.0 months. Only 5 (11%) of 44 pts had radiographic bone progression; median time to radiographic bone progression was not reached. Median OS was 24.4 months. Median time to first SSE and SSE-free survival were 16.7 and 12.8 months, respectively. Conclusions: Re-treating with Ra-223 was well tolerated in this select pt population, led to minimal hematologic toxicity, and provided continued disease control in bone at 2-year follow-up. Clinical trial information: NCT01934790.
Hepatitis B vaccine. Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United StatesSzmuness, W., Stevens, C. E., Harley, E. J., Zang, E. A., Oleszko, W. R., William, D. C., Sadovsky, R., Morrison, J. M. and Kellner, A. (1980). New England Journal of Medicine, 303, 833
Journal: Journal of Infection (1981)
Publication of National Strategic Plan for Early Detection and Control of Breast and Cervical Cancers
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chance, continuity, and change in hospital mortality rates. Coronary artery bypass graft patients in California hospitals, 1983 to 1989
Authors: H. S. Luft
Journal: JAMA (1993)

<h3>Objective.</h3> —To assess whether risk-adjusted mortality rates for hospitals reflect primarily chance variation. <h3>Design.</h3> —Observation over time. <h3>Setting.</h3> —All 115 California hospitals with five or more coronary artery bypass graft (CABG) patients in any year 1983 to 1989. <h3>Patients.</h3> —All CABG patients aged 18 years and older excluding those with other open heart procedures and percutaneous transluminal coronary angioplasty on the day of CABG surgery (n=132 750). <h3>Outcome Measure.</h3> —Inpatient mortality adjusted for age, gender, chronic comorbidities, timing of surgery, and presence of additional procedures. <h3>Methods.</h3> —Data were derived from routinely collected hospital discharge abstracts. Observed and expected semiannual mortality rates were examined for each hospital to identify consistent patterns over time. Using the quartile of patients with the highest predicted risk (average mortality, 10%), high- and low-outlier hospitals were identified from 2 consecutive years of pooled data and outcomes 2 years later were examined. Each hospital-year observation was also examined individually to identify outliers and to assess differences for observed and expected death rates, patient volume, and other characteristics. <h3>Results.</h3> —Some hospitals showed consistently lower-than-expected inpatient mortality. Some hospitals had periods of significantly higher-than-expected mortality followed by a correction. High-outlier hospitals that were selected based on 2 years of data had mortality rates 2 years later that averaged 31% above expected, while low-outlier hospitals had rates 2 years later that averaged 28% below expected. On a contemporaneous basis, high outliers had proportionately more transfers to other acute care hospitals and longer postoperative stays among survivors. <h3>Conclusions.</h3> —Risk-adjusted outcomes for CABG patients derived from administrative data exhibit substantial patterns of consistency. Such patterns cannot be detected for low-risk patients but are evident for the top quartile of patients stratified by risk. Even with reporting lags and changes in hospital outcomes over time, a policy of channeling high-risk patients away from high-outlier hospitals and toward low-outlier hospitals could lower the overall risk-adjusted mortality rate by 54%. (<i>JAMA</i>. 1993;270:331-337)
A management strategy for sore throat
Authors: A. L. Komaroff
Journal: JAMA (1978)

THE CLINICIAN often regards the problem of a sore throat as intellectually trivial and clinically unimportant. Neither attitude is justified. Many etiologic agents remain to be identified, the differential diagnosis is difficult, determination of a treatment strategy is complicated, and the symptom of a sore throat can be associated with or lead to serious illness. Primarily because of its prevalence, sore throat is also a costly problem. Data from the National Ambulatory Medical Care Survey, coupled with cost studies by our group, suggest that as much as $300 million per year may be spent on laboratory tests and medications ordered for this problem. A recognition of the substantial costs involved makes it imperative that the actions taken by clinicians in the evaluation and treatment of patients with sore throat be carefully scrutinized. I will present an explicit strategy for management, while discussing some important aspects of the diseases in question.
CSF eosinophilia following myelography
Authors: H. P. Holley
Journal: JAMA (1979)

WE recently encountered a patient in whom eosinophilic meningitis developed following myelography with iophendylate (Pantopaque). This unusual reaction has been described previously in only two patients<sup>1</sup>and, to our knowledge, never in the English language literature. <h3>Report of a Case</h3> A 56-year-old man was admitted to the Baltimore Veterans Administration Hospital with a history of increasing weakness on the left side and neck pain exacerbated by motion over the previous six weeks. The patient had a long history of left otitis media and alcohol abuse; he had also noted a recent decrease in the force of micturition. Abnormal findings on physical examination were a perforated left tympanic membrane and a moderately enlarged prostate. Neurological examination demonstrated diminished hearing on the left, which was confirmed by audiometry. There were hypesthesia, hypalgesia, and a deficit of vibratory sensation involving the entire left leg to the groin. Weakness and decreased deep tendon
Impact of external-beam radiation therapy on outcomes among patients with resected gastric cancer: A multi-institutional analysis.
Authors: Aslam Ejaz, Gaya Spolverato, Yuhree Kim, Malcolm Hart Squires, Sharon M. Weber, George A. Poultsides, Konstantinos Ioannis Votanopoulos, Mark Bloomston, Ryan C. Fields, David A. Kooby, Alexandra W. Acher, David J. Worhunsky, Doug S. Swords, Neil Saunders, Linda X. Jin, Clifford Suhyun Cho, Carl Richard Schmidt, Joseph M. Herman, Shishir K. Maithel, Timothy M. Pawlik
Journal: Journal of Clinical Oncology (2014)

4011 Background: Use of perioperative chemotherapy (CTx) alone versus chemo-radiation therapy (cXRT) in the treatment of resectable gastric cancer remains varied. We sought to define the utilization and effect of CTx alone versus cXRT on patients having undergone curative-intent resection for gastric cancer. Methods: Using the multi-institutional U.S. Gastric Cancer Collaborative database, we identified 505 patients between 2000 and 2012 with gastric cancer who received perioperative therapy in addition to curative-intent resection. The impact of perioperative therapy on survival was analyzed by the use of propensity-score matching of clinicopathologic factors among patients who received CTx alone versus cXRT. Results: Median patient age was 62 years and the majority of patients were male (58%). Surgical resection involved either partial gastrectomy (54%) or total gastrectomy (46%). On pathology, median tumor size was 5.0 cm; most patients had a T3 (37%) or T4 (36%) lesion and lymph node metastasis (74%). Margin status was R0 in most patients (89%). 211 (42%) patients received perioperative CTx alone whereas the remaining 294 (58%) patients received 5-FU based cXRT. Factors associated with receipt of cXRT were younger age (OR 0.98), T3 tumors (OR 1.52), and lymph node metastasis (OR 2.03) (all P < .05). Recurrence occurred in 214 (39%) patients. At a median follow-up of 28 months, median overall survival (OS) was 33.4 months and 5-year survival was 36.7%. Factors associated with worse OS included tumor size (HR 1.1), T-stage (HR 1.5), and lymph node metastasis (HR 1.58) (all P<0.05). In contrast, receipt of cXRT was associated with improved long-term OS (CTx alone: 21 months vs. cXRT 45 months; p<0.001). In the propensity-matched multivariate model that adjusted for tumor size, T-stage, and nodal status, cXRT remained associated with an improved long-term disease-free (HR 0.43) and overall (HR 0.41) survival (both P<0.001). Conclusions: XRT was utilized in 58% of patients undergoing curative-intent resection for gastric cancer. Using propensity-matched analysis, cXRT was an independent factor associated with improved recurrence-free and overall survival.
Future Face
Authors: Graham Easton
Journal: BMJ (2004)

An exhibition at the Science Museum, London SW7, from 1 October 2004 until 13 February 2005. Admission free www.sciencemuseum.org.uk/exhibitions/futureface/ Rating: ![Graphic][1]</img>![Graphic][2]</img>![Graphic][3]</img>![Graphic][4]</img> T he Science Museum has had to evolve as science and its relationship with the public have become more sophisticated. “Future Face” is a great example of how it has grown up—a blend of art and science that really gets you thinking about what faces are, what they mean, and what they might look like in the future. For the traditionalists there are still some texts and even a few (awesome) buttons to press—just don't expect to go home with all the answers. The “Future Face” project is the brainchild of Sandra Kemp, director of research at the Royal College of Art, and it has taken her five years to bring together. Unlike many trendy “arts meets science” projects, where the art is simply there to “sex up” the science, this one really works because scientists and artists have been pondering the mysteries of the face in their different ways for … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif [3]: /embed/inline-graphic-3.gif [4]: /embed/inline-graphic-4.gif
The QT interval and serum ionized calcium
Authors: W. M. Rumancik
Journal: JAMA (1978)

The correlation between serum ionized calcium (Ca<sup>++</sup>) levels and three ECG QT intervals (Q-<sub>O</sub>T<sub>C</sub>, Q-<sub>A</sub>T<sub>c</sub>, and Q-<sub>E</sub>T<sub>C</sub>) was assessed in 20 adult patients. The relationship between each QT interval and Ca<sup>++</sup>level, based on 209 Ca<sup>++</sup>determinations through a range of 1.0 to 4.0 mEq/liter, is best described by a hyperbolic function. Although Q-<sub>O</sub>T<sub>C</sub>and Q-<sub>A</sub>T<sub>C</sub>predict Ca<sup>++</sup>levels more accurately than Q-<sub>E</sub>T<sub>C</sub>, all QT intervals are clinically unreliable as guides to the presence of hypercalcemia. Similarly, the usefulness of the QT intervals in the diagnosis of hypocalcemia is limited by the wide distribution of normal values. (<i>JAMA</i>240:366-368, 1978)
International Symposium: The Genetics of Development
Journal: JNCI Journal of the National Cancer Institute (1985)

Journal Article International Symposium: The Genetics of Development Get access JNCI: Journal of the National Cancer Institute, Volume 74, Issue 4, April 1985, Page 953, https://doi.org/10.1093/jnci/74.4.953-e Published: 01 April 1985